<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2608210985
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Axyla
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TERIFLUNOMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2534.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Shilpa Medicare Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Shilpa Medicare Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA31
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Axyla is</strong></p><p><strong>Axyla </strong>contains the active substance teriflunomide which is an immunomodulatory agent and adjusts the</p><p>immune system to limit its attack on the nervous system.</p><p><strong>What Axyla is used for</strong></p><p><strong>Axyla </strong>is used in adults to treat relapsing - remitting multiple sclerosis (MS).</p><p><strong>What multiple sclerosis is</strong></p><p>MS is a long-term illness that affects the central nervous system (CNS).</p><p>The CNS is made up of the brain and spinal cord. In multiple sclerosis, inflammation destroys the protective sheath (called myelin) around the nerves in the CNS.</p><p>This loss of myelin is called demyelination.</p><p>This stops nerves from working properly.</p><p>People with relapsing form of multiple sclerosis will have repeated attacks (relapses) of physical symptoms caused by their nerves not working properly.</p><p>These symptoms vary from patient to patient but usually involve:</p><p>&bull; difficulty walking</p><p>&bull; vision problems</p><p>&bull; balance problems.</p><p>Symptoms may disappear completely after the relapse is over, but over time, some problems may remain between relapses.</p><p>This can cause physical disabilities that may interfere with your daily activities.</p><p><strong>How Axyla works</strong></p><p><strong>Axyla </strong>helps to protect against attacks on the central nervous system by the immune system by limiting the increase of some white blood cells (lymphocytes).</p><p>This limits the inflammation that leads to nerve damage in MS.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Axyla:</strong></p><p>-- if you are allergic to teriflunomide or any of the other ingredients of this medicine (listed in section 6),</p><p>-- if you have severe liver problems,</p><p>-- if you are <strong>pregnant</strong>, think you may be pregnant, or are breast-feeding,</p><p>-- if you suffer from a serious problem which affects your immune system e.g. acquired immunodeficiency syndrome (AIDS),</p><p>-- if you have a serious problem with your bone marrow, or if you have low numbers of red or white cells in your blood or a reduced number of blood platelets,</p><p>-- if you are suffering from a serious infection,</p><p>-- if you have severe kidney problems which require dialysis,</p><p>-- if you have very low levels of proteins in your blood (hypoproteinaemia), If you are not sure, talk to your doctor or</p><p>pharmacist before taking this medicine.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking <strong>Axyla </strong>if:</p><p>-- you have liver problems and/or if you drink large amounts of alcohol. Your doctor will carry out blood tests before and during treatment to check how well your liver is working. If your test results show a problem with your liver, your doctor may stop your treatment with <strong>Axyla</strong>. Please read section 4.</p><p>-- you have high blood pressure (hypertension) whether it is controlled with medicines or not. <strong>Axyla </strong>can cause an increase in blood pressure. Your doctor will check your blood pressure before the start of treatment and regularly thereafter. Please read section 4.</p><p>-- you have an infection. Before you take <strong>Axyla</strong>, your doctor will make sure you have enough white blood cells and platelets in your blood. As <strong>Axyla </strong>decreases the number of white cells in the blood this may affect your ability to fight the infection. Your doctor may do blood tests to check your white blood cells if you think you have an infection. Please read section 4.</p><p>-- you have severe skin reactions.</p><p>-- you have respiratory symptoms.</p><p>-- you have weakness, numbness and pain in the hands and feet.</p><p>-- you are going to have a vaccination.</p><p>-- you take leflunomide with <strong>Axyla</strong>.</p><p>-- you are switching to or from <strong>Axyla</strong>.</p><p>-- you are lactose intolerant.</p><p>-- you are due to have a specific blood test (calcium level). Falsely low levels of calcium can be detected.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>Axyla </strong>should not be used in children and adolescents under 18 years of age.</p><p>This is because the effects of the medicine in this age group are not known.</p><p>&nbsp;</p><p><strong>Other medicines and Axyla</strong></p><p>Tell your your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>This includes medicines obtained without a prescription.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following:</p><p>-- leflunomide, methotrexate and other medicines that affect the immune system (often called immunosuppressants or immunomodulators)</p><p>-- rifampicin (a medicine used to treat tuberculosis and other infections)</p><p>-- carbamazepine, phenobarbital, phenytoin for epilepsy</p><p>-- St John&rsquo;s wort (a herbal medicine for depression)</p><p>-- repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes</p><p>-- daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer</p><p>-- duloxetine for depression, urinary incontinence or in kidney disease in diabetics</p><p>-- alosetron for the management of severe diarrhea</p><p>-- theophylline for asthma</p><p>-- tizanidine, a muscle relaxant</p><p>-- warfarin, an anticoagulant used to make the blood thinner (i.e. more fluid) in order to avoid blood clots</p><p>-- oral contraceptives (containing ethinylestradiol and levonorgestrel)</p><p>-- cefaclor, benzylpenicillin (penicillin G), ciprofloxacin for infections</p><p>-- indometacin, ketoprofen for pain or inflammation</p><p>-- furosemide for heart disease</p><p>-- cimetidine for reducing gastric acid</p><p>-- zidovudine for HIV infection</p><p>-- rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol)</p><p>-- sulfasalazine for inflammatory bowel disease or rheumatoid arthritis</p><p>-- cholestyramine for high cholesterol or relief from itching in liver disease</p><p>-- activated charcoal to reduce absorption of medicines or other substances</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Do not </strong>take <strong>Axyla </strong>if you are, or think you may be <strong>pregnant</strong>. If you are pregnant or become pregnant while taking <strong>Axyla</strong>, the risk of having a baby with birth defects is increased.</p><p>Women of childbearing potential must not take this medicine without using reliable contraceptive measures.</p><p>Tell your doctor if you plan to become pregnant after stopping treatment with <strong>Axyla</strong>, as you need to ensure that most of this medicine has left your body before trying to become pregnant.</p><p>The elimination of the active substance may take up to 2 years to occur naturally.</p><p>The time can be reduced to a few weeks by taking certain medicines which speed up removal of <strong>Axyla </strong>from your body.</p><p>In either case it should be confirmed by a blood test that the active substance has</p><p>been sufficiently removed from your body and you need confirmation from your</p><p>treating physician that the blood level of <strong>Axyla </strong>is low enough to allow you to become pregnant.</p><p>For further information on the laboratory testing please contact your doctor.</p><p>If you suspect that you are pregnant while taking <strong>Axyla </strong>or in the two years after you have stopped treatment, you must contact your doctor <strong>immediately</strong> for a pregnancy test. If the test confirms that you are pregnant, your doctor may suggest treatment with certain medicines to remove <strong>Axyla </strong>rapidly and sufficiently from your body, as this may decrease the risk to your baby.</p><p>Contraception</p><p>You must use an effective method of contraception during and after treatment with <strong>Axyla</strong>. Teriflunomide remains in your blood for a long time after you stop taking it. Continue to use effective contraception after you stop treatment.</p><p>&bull; Do this until the levels of <strong>Axyla </strong>in your blood are low enough - your</p><p>doctor will check this.</p><p>&bull; Talk with your doctor about the best method of contraception for you and any</p><p>potential need for contraception change.</p><p>Do not take <strong>Axyla </strong>when you are breast-feeding, as teriflunomide passes into the breast milk.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p><strong>Axyla </strong>might make you feel dizzy which may impair your ability to concentrate and react. If you are affected, do not drive or use machines.</p><p>&nbsp;</p><p><strong>Axyla contains lactose</strong></p><p><strong>Axyla </strong>contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before this medicine.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with <strong>Axyla </strong>will be overseen by a doctor who is experienced in the treatment of multiple sclerosis.</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>The recommended dose is one film-coated tablet (14 mg) daily.</p><p>Route/method of administration <strong>Axyla </strong>is for oral use. <strong>Axyla </strong>is taken</p><p>every day as a single daily dose at any time of the day.</p><p>You should swallow the tablet whole with some water.</p><p><strong>Axyla </strong>may be taken with or without food.</p><p><strong>If you take more Axyla than you should</strong></p><p>If you have taken too much <strong>Axyla</strong>, call your doctor straight away. You may experience side effects similar to those described in section 4 below.</p><p><strong>If you forget to take Axyla</strong></p><p>Do not take a double dose to make up for a forgotten tablet. Take your next dose at the scheduled time.</p><p><strong>If you stop taking Axyla</strong></p><p>Do not stop taking <strong>Axyla </strong>or change your dose without talking to your doctor first.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects may happen with this medicine.</p><p><strong>Serious side effects</strong></p><p><strong>Tell your doctor immediately, if you notice any of the following serious side effects:</strong></p><p>-- allergic reactions which might include symptoms of rash, hives, swelling of lips, tongue or face or sudden difficulty breathing</p><p>-- severe skin reactions which might include symptoms of skin rash, blistering, or ulcers in your mouth</p><p>-- severe infections or sepsis (a potentially life-threatening type of infection) which might include symptoms of high fever, shaking, chills, reduced urine flow, or confusion</p><p>-- serious liver disease which might include symptoms of yellowing of your skin or the whites of your eyes, darker urine than normal, unexplained nausea and vomiting, or abdominal pain</p><p>-- inflammation of the lungs which might include symptoms of shortness of breath or persistent cough</p><p>-- inflammation of the pancreas which might include symptoms of severe pain in the upper abdominal area that may also be felt in your back, nausea, or vomiting</p><p><strong>Other side effects can occur with the following frequencies</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><p>-- Headache</p><p>-- Diarrhoea, feeling sick</p><p>-- Increase in ALT (increase in blood levels of certain hepatic enzymes) shown in tests</p><p>-- Hair thinning</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>-- Influenza, upper respiratory tract infection, urinary tract infection, bronchitis, sinusitis, sore throat and discomfort when swallowing, cystitis, gastroenteritis viral, oral herpes, tooth</p><p>infection, laryngitis, fungal infection of the foot</p><p>-- Laboratory values: a decrease in the number of red blood cells (anaemia), changes in liver and white blood cell test results (see section 2), as well as elevations in a muscle enzyme (creatine phosphokinase) have been observed</p><p>-- Mild allergic reactions</p><p>-- Feeling anxious</p><p>-- Pins and needles, feeling weak, numb, tingling or pain in the lower back or leg (sciatica); feeling numb, burning, tingling or pain in the hands and fingers (carpal tunnel syndrome)</p><p>-- Feeling your heartbeat</p><p>-- Increase in blood pressure</p><p>-- Being sick (vomiting), toothache, upper abdominal pain</p><p>-- Rash, acne</p><p>-- Pain of the tendons, joints, bones, muscle pain (musculoskeletal pain)</p><p>-- Needing to urinate more often than usual</p><p>-- Heavy periods</p><p>-- Pain</p><p>-- Lack of energy or feeling weak (asthenia)</p><p>-- Weight loss</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>-- Decrease in the number of blood platelets (mild thrombocytopenia)</p><p>-- Increased feeling or sensitivity, especially in the skin; stabbing or throbbing pain along one or more</p><p>nerves, problems in the nerves of the arms or legs (peripheral neuropathy)</p><p>-- Nail disorders</p><p>-- Post-traumatic pain</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>-- Severe infections (including sepsis)</p><p>-- Severe allergic reactions (including anaphylaxis)</p><p>-- Pulmonary reaction (interstitial lung disease, ILD)</p><p>-- Inflammation of the liver, pancreas, or mouth/lips</p><p>-- Severe skin reactions</p><p>-- Abnormal levels of fats (lipids) in the blood</p><p>-- Psoriasis</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton, protective sleeve, and wallet after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p dir="RTL">.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.What Axyla contains</strong></p><p>-- The active substance is teriflunomide. Each tablet contains 14 mg of teriflunomide.</p><p>-- The other ingredients are lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), hydroxypropylcellulose, Colloidal Silicon Dioxide , magnesium stearate Opadry Blue 03B505062 and Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Axyla 14 mg film-coated tablets (tablets) are pale blue to pastel blue, pentagonal film-coated tablets with imprint on one side (‘S28’) and plain on the other side.
Axyla is available in pack size of 28 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p><strong>Manufacturer by: </strong></p><p>Shilpa Medicare Limited - India for MS Pharma-Saudi.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sep,2021
SPM-14-0025

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو أكسيلا؟</strong></p><p dir="RTL">يحتوي <strong>أكسيلا</strong> على مادة تيريفلونوميد التي تعد عاملًا مناعيًا وتقوم بتعديل النظام المناعي ليحد من هجومه على الجهاز العصبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي دواعي استعمال أكسيلا؟</strong></p><p dir="RTL">يستخدم <strong>أكسيلا</strong> للبالغين لمعالجة التصلب المتعدد المتردد-الانتكاسي.</p><p dir="RTL">ما هو التصلب المتعدد</p><p dir="RTL">يعد التصلب المتعدد مرض طويل الأجل يقوم بالتأثير على النظام العصبي المركزي. يتكون الجهاز العصبي المركزي من الدماغ والنخاع الشوكي. في حالة التصلب المتعدد، يقوم الالتهاب بتدمير الغمد الوقائي (يسمى الميالين) الموجود حول الأعصاب في الجهاز العصبي المركزي. تسمى إزالة الميالين، وهذا من شأنه أن يمنع الأعصاب من العمل بشكل سليم.</p><p dir="RTL">سيعاني الأشخاص الذين يعانون من الأشكال الانتكاسية للتصلب المتعدد من نوبات متكررة (انتكاسات) من الأعراض الجسدية الناجمة عن عدم عمل الأعصاب بشكل سليم.</p><p dir="RTL">تختلف هذه الأعراض من مريض إلى أخر ولكنها تتضمن عادةً:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في المشي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التوازن</p><p dir="RTL">قد تختفي الأعراض بالكامل بعد انتهاء الانتكاسة، لكن مع مرور الوقت، قد تظل بعض المشاكل قائمة بين الانتكاسات. يمكن لهذا أن يسبب إعاقات جسدية من شأنها أن تؤثر على أنشطتك اليومية.</p><p dir="RTL"><strong>كيف يعمل أكسيلا؟</strong></p><p dir="RTL">يساعد <strong>أكسيلا</strong> على الحماية من النوبات التي يتعرض لها الجهاز العصبي المركزي بواسطة الجهاز المناعي عن طريق الحد من زيادة بعض من خلايا الدم البيضاء (الخلايا اللمفية). من شأن هذا أن يحد من الالتهاب الذي يؤدي إلى تلف في الأعصاب في حالة التصلب المتعدد.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أكسيلا:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية من مادة تيريفلونوميد أو أي مكون أخر لهذا الدواء (المُدرج في القسم 6)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل حادة في الكبد،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو تعتقدي بأنكِ حامل أو تقومين بالإرضاع الطبيعي،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل خطيرة من شأنها أن تؤثر على جهازك المناعي، على سبيل المثال متلازمة نقص المناعة المكتسبة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل خطيرة في نخاع العظم أو كانت لديك أعداد قليلة من خلايا الدم الحمراء أو البيضاء في دمك أو أعداد قليلة من الصفائح الدموية،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى خطيرة،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل حادة في الكلى بحيث تتطلب غسيل الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مستويات منخفضة من البروتين في دمك (نقص بروتين الدم)،</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول هذا الدواء إذا لم تكن متأكدًا.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>تحدث إلى طبيبك أو الصيدلي الخاص بك قبل تناول دواء أكسيلا:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل في الكبد وإذا شربت كميات كبيرة من الكحوليات أو أحدهما. سيقوم طبيبك بإجراء فحوصات الدم قبل وأثناء العلاج للتحقق من مدى كفاءة عمل كبدك. إذا أظهرت نتائج الفحص وجود مشكلة في كبدك، فقد يقوم طبيبك بإيقاف تناولك لدواء <strong>أكسيلا</strong>. يرجى قراءة القسم 4.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع في ضغط الدم (ارتفاع ضغط الدم) سواء كان يتم التحكم فيه بواسطة هذه الأدوية أو لا. يمكن أن يسبب دواء <strong>أكسيلا</strong> ارتفاع في ضغط الدم. سيقوم طبيبك بالتحقق من ضغط الدم لديك قبل بدء العلاج وبشكل منتظم بعد ذلك. يرجى قراءة القسم 4.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك عدوى. سيقوم طبيبك بالتأكد من أن يكون لديك عدد كافي من خلايا الدم البيضاء والصفائح الدموية في دمك قبل تناول دواء <strong>أكسيلا</strong>. نظرًا لأن دواء <strong>أكسيلا</strong> يقوم بتقليل عدد خلايا الدم البيضاء في الدم، فمن شأن هذا أن يؤثر على قدرتك في مكافحة تلك العدوى. يمكن أن يقوم طبيبك بإجراء فحوصات الدم للتحقق من خلايا الدم البيضاء الموجودة في دمك وذلك في حال اعتقادك بأنك أصيبت بتلك العدوى. يرجى قراءة قسم 4.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تفاعلات جلدية حادة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أعراض في الجهاز التنفسي.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك ضعف وتخدر وألم في اليدين والقدمين<strong>.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تنوي أخذ لقاح.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا تناولت تيريفلونوميد مع <strong>أكسيلا</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا قمت بالتبديل من أو إلى <strong>أكسيلا</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت غير قادر على تحمل اللاكتوز.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان من المقرر أن تقوم بإجراء فحص دم محدد (مستوى الكالسيوم). يمكن اكتشاف مستويات الكالسيوم المنخفضة الزائفة.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يجب أن يتناول الأطفاق والمراهقون دون سن 18 عامًا دواء <strong>أكسيلا</strong> وذلك لأن تأثيرات هذا الدواء غير معروفة على تلك الفئات العمرية.</p><p dir="RTL"><strong>أدوية أخرى ودواء أكسيلا</strong></p><p dir="RTL">قم بإخبار طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو ستتناول أية أدوية أخرى. يشمل الأدوية التي لا تتطلب وصفة طبية. على وجه الخصوص، أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أي مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لفلونوميد وميثوتركسيت وأية أدوية أخرى من شأنها أن تؤثر على جهاز المناعة (تسمى عادةً مثبطات المناعة أو المعدلات المناعية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (دواء يتم استخدامه لعلاج السُل والعدوى الأخرى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازبيين وفينوباربيتال وفينيتوين لعلاج الصرع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (طب عشبي لعلاج الاكتئاب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريباغلينيد أو بيوغليتازون أو ناتيغلينيد أو روزيغليتازون لعلاج داء السكري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داونوروبيسين أو دوكسوروبيسين أو باكليتاكسيل أو توبوتيكان لعلاج مرض السرطان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دولوكسيتين لعلاج الاكتئاب أو سلس البول أو أمراض الكلى لمرضى السكر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألوسيترون لمعالجة الإسهال الشديد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيوفيلين لعلاج الربو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيزانيدين، مرخي للعضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين وهو دواء مضاد للتخثر يتم استخدامه لتقليل تخثر الدم (أي يكون سائل بشكل أكبر) ولذلك لتجنب تجلط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حبوب منع الحمل (تشمل إيثينيل إستراديول وليفونورجيستريل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيفاكلور وبنزيل بنسلين (بنسلين ج) سيبروفلوكساسين لعلاج العدوى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إندوميتاسين وكيتوبروفين لعلاج الألم أو الالتهاب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فوروسيميد لعلاج أمراض القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيميتيدين لتقليل الحمض المعدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيدوفيدين لعلاج فيروس نقص المناعة المكتسب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رسيوفاستاتين وسيمفاستاتين وأتورفاستاتين وبرافاستاتين لعلاج فَرْطُ كوليستيرولِ الدَّم (ارتفاع نسبة الكوليسترول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلفاسالازين لعلاج داء الأمعاء الالتهابي أو التهاب المفاصل الروماتويدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوليسترامين لعلاج ارتفاع نسبة الكوليسترول للتخفيف من الحكة في مرض الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفحم المنشط للتقليل من امتصاص الأدوية أو غيرها من المواد</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يجب تناول دواء <strong>أكسيلا</strong> إذا كنتِ حاملًا أو تعتقدين بأنكِ حامل. إذا كنتِ حامل أو أصبحتِ حاملًا أثناء تناول دواء <strong>أكسيلا</strong>، فعندئذ تزداد نسبة إنجاب طفل لديه تشوهات خلقية. لا يجب أن تتناول النساء ممن في سن الإنجاب هذا الدواء دون استخدام وسائل منع حمل موثوقة.</p><p dir="RTL">أخبري طبيبك في حال كنت تخططين لأن تصبحين حاملًا عقب التوقف عن تناول دواء <strong>أكسيلا</strong> وذلك حسب الحاجة وذلك للتأكد من عدم وجود أية آثار للدواء في جسدك وذلك قبل محاولة أن تصبحي حامل. قد يستغرق التخلص من المادة الفعالة سنتين ليحدث ذلك بشكل طبيعي. يمكن تقليل هذا الوقت لبضعة أسابيع عن طريق تناول أدوية محددة تعمل على زيادة سرعة التخلص من دواء <strong>أكسيلا</strong> من جسدك. في كلتا الحالتين، يجب إجراء فحص الدم وذلك للتأكد من عدم وجود المادة الفعالة بشكل كافي في جسدك وتحتاج إلى تأكيد من طبيبك المعالج أن مستوى الدم الخاص بدواء <strong>أكسيلا</strong> يكون منخفض بشكل كافي للسماح لكِ بالحمل.</p><p dir="RTL">يرجى التواصل مع طبيبك للمزيد من المعلومات حول الفحوصات المختبرية.</p><p dir="RTL">إذا كنت تشكين بأنكِ حامل أثناء تناول دواء <strong>أكسيلا</strong> أو خلال السنتين التاليتين من التوقف عن تناول هذا الدواء، فيجب عليكِ التواصل مع طبيبك على الفور لإجراء ف الحمل. إذا أكد الاختبار الحمل، فيمكن لطبيبك اقتراح علاج مع تناول أدوية أخرى وذلك لإزالة هذا الدواء بشكل سريع وكافي من جسدك، من الممكن أن يؤدي هذا إلى تقليل المخاطر التي قد يتعرض لها طفلك.</p><p dir="RTL"><strong><u>منع الحمل</u></strong></p><p dir="RTL">يجب استخدام وسيلة منع حمل فعالة أثناء وبعد تناول دواء <strong>أكسيلا</strong>. يظل تيريفلونوميد في جسدك لمدة طويلة حتى بعد التوقف عن تناوله. يجب الاستمرار في استخدام وسيلة منع حمل فعالة بعد التوقف عن تناول الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب الاستمرار في استخدام وسيلة منع حمل وذلك حتى تنخفض مستويات دواء <strong>أكسيلا</strong> بشكل كافي في دمك-سيقوم طبيبك بالتحقق من ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدثي مع طبيبك عن أفضل وسيلة منع حمل تناسبك وأية حاجة محتملة لتغيير وسيلة منع الحمل.</p><p dir="RTL">لا يجب عليكِ تناول دواء <strong>أكسيلا</strong> أثناء الرضاعة الطبيعية حيث تنتقل مادة تيريفلونوميد إلى لبن الثدي.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك دواء <strong>أكسيلا</strong> تشعر بالدوار مما قد يضعف قدرتك على التركيز والتفاعل. إذا كنت متأثرًا بذلك الدواء، فعندئذ لا يمكنك القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>يحتوي دواء أكسيلا على اللاكتوز</strong></p><p dir="RTL">يحتوي دواء <strong>أكسيلا</strong> على اللاكتوز (نوع من أنواع السكر). إذا أخبرك طبيبك بأنك تعاني من ضعف تحمل السكريات، فيجب التواصل معه قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم الإشراف على دورة العلاج بدواء <strong>أكسيلا</strong> من قبل طبيب ذو خبرة في اختبار هذا الدواء على التصلب المتعدد.</p><p dir="RTL">يجب دائمًا تناول الجرعة التي يحددها طبيبك. قم باستشارة طبيبك إذا لم تكن متأكدًا.</p><p dir="RTL">إن الجرعة الموصي بها هي قرص واحد مغلف بطبقة رقيقة (14 ملغم) يوميًا.</p><p dir="RTL"><u>وسيلة/ طريقة العلاج</u></p><p dir="RTL">يتم تناول دواء <strong>أكسيلا</strong> عن طريق الفم، ويتم تناوله كجرعة واحدة يوميًا في أي وقت من اليوم.</p><p dir="RTL">يجب بلع القرص بالكامل مع بعض المياه.</p><p dir="RTL">يمكن تناول دواء <strong>أكسيلا</strong> مع أو بدون تناول الطعام.</p><p dir="RTL"><strong>في حال قمت بتناول جرعة زائدة من دواء أكسيلا </strong></p><p dir="RTL">إذا قمت بتناول جرعة كبيرة من <strong>أكسيلا</strong>، فيجب عليك الاتصال بطبيبك على الفور. قد تواجه تأثيرات جانبية مشابهة لتلك الموضحة في القسم 4 أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال نسيان تناول دواء أكسيلا</strong></p><p dir="RTL">لا تتناول جرعة مزدوجة لكي تعوض جرعة القرص الذي نسيت تناوله. قم بأخذ جرعتك التالية في الوقت المحدد.</p><p dir="RTL"><strong>في حال توقفت عن تناول أكسيلا</strong></p><p dir="RTL">لا تتوقف عن تناول <strong>أكسيلا</strong> أو لا تقم بتغيير جرعتك دون التحدث مع طبيبك أولًا.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية بشأن استعمل هذا الدواء، فيرجى سؤال طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>. ما هي الأعراض الجانبية المتوقعة.</strong></p><p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء أعراض جانبية على الرغم من عدم حدوثها للجميع.</p><p dir="RTL">يمكن أن يُحدث هذا الدواء الأعراض الجانبية التالية.</p><p dir="RTL"><strong>أعراض جانبية خطيرة</strong></p><p dir="RTL"><strong>قم بإخبار طبيبك على الفور في حال قمت بملاحظة أي من الأعراض الجانبية الخطيرة التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية التي تشمل أعراض الطفح أو الشرى أو تورم الشفاه أو اللسان أو الوجه أو صعوبة مفاجئة في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل جلدية شديدة قد تشمل أعراض الطفح الجلدي أو ظهور البثور أو القرح في لسانك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى حادة أو تعفن الدم (نوع محتمل من العدوى المهددة للحياة) التي قد تشمل أعراض الحمى الشديدة أو الرعاش أو القشعريرة أو انخفاض تدفق البول أو الاضطراب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الكبد الحاد التي قد تشمل أعراض اصفرار جلدك أو بياض العينين أو اللون الداكن للبول أكثر عن المعتاد او غثيان غير مفسر أو القيء أو ألم في البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين الذي قد يشمل أعراض ضيق التنفس أو السعال المتواصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس الذي قد يشمل أعراض ألم حاد في منطقة البطن العلوية الذي قد تشعر به أيضًا في ظهرك أو القيء أو الغثيان</p><p dir="RTL"><strong>قد تحدث أعراض جانبية أخرى مع التكرارات التالية</strong></p><p dir="RTL"><strong>شائع للغاية </strong>(قد تؤثر على 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال أو الشعور بالمرض</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في ناقلة أمين الألانين (زيادة في مستويات الدم الخاصة بإنزيمات كبدية محددة) الموضحة في الفحوصات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL"><strong>الشائعة (</strong>قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنفلونزا وعدوى الجهاز التنفسي العلوي وعدوى المسالك البولية والالتهاب الرئوي والتهاب الجيوب الأنفية والتهاب الحلق وعدم الراحلة عند البلع والتهاب المثانة والتهاب المعدة والأمعاء الفيروسي الهربس الفموي وعدوى الأسنان والتهاب الحنجرة وعدوى فطرية في القدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيم المختبرية: انخفاض عدد خلايا الدم الحمراء (فقر الدم) وتغيرات في نتائج فحص الكبد وخلايا الدم البيضاء (يرجى الاطلاع على قسم 2) بالإضافة إلى أنه تم ملاحظة حدوث ارتفاعات في إنزيم العضلات (كرياتين فوسفوكيناز)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية بسيطة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالقلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دبابيس أو إبر أو الشعور بالضعف أو التخدر أو النخر أو ألم في أسفل الظهر أو الساق (عرق النسا) أو الشعور بتخدر أو حرق أو نخر أو ألم في اليدين والأصابع (متلازمة النفق الرسغي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بنبضات قلبك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالمرض (الغثيان) أو ألم الأسنان أو ألم في البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح أو حب الشباب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في أوتار العضلات أو المفاصل أو العظام أو ألم في العضلات أو ألم عضلي هيكلي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحاجة إلى التبول أكثر من المعتاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دورات شهرية غزيرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في الطاقة أو الشعور بالضعف (الضعف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">غير شائعة (<strong>قد تؤثر على ما يصل إلى 1 من كل 100 شخص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدموية (قلة الصفائح بشكل بسيط)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الإحساس أو الحساسية لا سيما في الجلد أو الوخز أو ألم الخفقان الذي ينتشر في واحد أو أكثر من الأعصاب أو مشاكل في أعصاب الذراعين أو الساقين (اعتلال الأعصاب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأظافر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام ما بعد الصدمة</p><p dir="RTL">غير شائعة (لا يمكن تقدير التكرار من البيانات المتوفرة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى شديدة (بما في ذلك تعفن الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية حادة (بما في ذلك فرط الحساسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل رئوي &nbsp;(مرض الرئة الخلالي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد أو البنكرياس أو الفم أو الشفتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل جلدية خطيرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات غير طبيعية من الدهون (الليبيدات) في الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صدفية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إبقاء هذا الدواء بعيدًا عن مرئ ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية التي توضع على العلبة الخارجية، يشير تاريخ انتهاء الصلاحية إلى أخر يوم من الشهر.</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 &deg;م.</p><p dir="RTL">يجب تخزينة في العبوة الخارجية لحمايته من الرطوبة.</p><p dir="RTL">&nbsp;لا تقم بالتخلص من أية من هذه الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. قم باستشارة الصيدلي الخاص بك عن طريقة التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ.ما يحتوي عليه أكسيلا</strong></p><p dir="RTL">- المادة الفعالة هي تيريفلوروموميد. كل قرص يحتوي على 14 ملغم من تيريفلوروموميد.</p><p dir="RTL">- المكونات الأخرى هي اللاكتوز أحادي الهيدرات وسليولوز دقيق التبلور ونشا الصوديوم جلايكولات (النوع أ) وهيدروكسي بروبيل سيليولوز وثنائي أكسيد السيليكون الغرواني وستيرات المغنيسيوم و أوبادري بلو 03 ,B505062 وماء مقطر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص <strong>أكسيلا</strong> 14 ملغم المغلفة (أقراص) هي أقراص مغلفة باللون الأزرق الفاتح إلى الأزرق الباستيل وخماسية الأضلاع&nbsp; ،منقوش عليها من جانب ب(28S) ومنبسطة على الجانب الآخر.</p><p dir="RTL">يتوفر <strong>أكسيلا</strong> في عبوة بحجم 28 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية</p><p dir="RTL">الرياض ، المملكة العربية السعودية .</p><p dir="RTL">&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:&nbsp; </strong><strong>&nbsp;</strong></p><p dir="RTL">شيلبا للرعاية الطبية المحدودة &ndash; الهند <strong>لصالح</strong><strong> </strong>إم إس فارما &ndash; المملكة العربية السعودية&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر،2021
SPM-14-0025

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Axyla 14 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 14 mg of teriflunomide.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Pale blue to pastel blue colored, pentagonal film coated tablets, debossed with “S28” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1 Therapeutic indications</strong></p><p><strong>Axyla </strong>is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The treatment should be initiated and supervised by a physician experienced in the management of multiple sclerosis.</p><p><u>Posology</u></p><p>The recommended dose of teriflunomide is 14 mg once daily.</p><p><u>Special populations</u></p><p><em>Elderly population</em></p><p><strong>Axyla </strong>should be used with caution in patients aged 65 years and over due to insufficient data on safety and efficacy.</p><p><em>Renal impairment</em></p><p>No dosage adjustment is necessary for patients with mild, moderate or severe renal impairment not undergoing dialysis.</p><p>Patients with severe renal impairment undergoing dialysis were not evaluated. Teriflunomide is contraindicated in this population (see section 4.3).</p><p><em>Hepatic impairment</em></p><p>No dosage adjustment is necessary for patients with mild and moderate hepatic impairment. Teriflunomide is contraindicated in patients with severe hepatic impairment (see section 4.3).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of teriflunomide in children aged from 10 to less than 18 years has not yet been established. There is no relevant use of teriflunomide in children aged from birth to less than 10 years for the treatment of multiple sclerosis.</p><p>No data are available.</p><p><u>Method of administration</u></p><p>The film-coated tablets are for oral use. The tablets should be swallowed whole with some water. <strong>Axyla </strong>can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Patients with severe hepatic impairment (Child-Pugh class C).
Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with teriflunomide and thereafter as long as its plasma levels are above 0.02 mg/l (see section 4.6). Pregnancy must be excluded before start of treatment (see section 4.6).
Breast-feeding women (see section 4.6).
Patients with severe immunodeficiency states, e.g. acquired immunodeficiency syndrome (AIDS).
Patients with significantly impaired bone marrow function or significant anaemia, leucopenia, neutropenia or thrombocytopenia.
Patients with severe active infection until resolution (see section 4.4).
Patients with severe renal impairment undergoing dialysis, because insufficient clinical experience is available in this patient group.
Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Monitoring</u></p><p><em>Before treatment</em></p><p>Before starting treatment with teriflunomide the following should be assessed:</p><p>&bull; Blood pressure</p><p>&bull; Alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)</p><p>&bull; Complete blood cell count including differential white blood cell and platelet count.</p><p><em>During treatment</em></p><p>During treatment with teriflunomide the following should be monitored:</p><p>&bull; Blood pressure</p><p>o Check periodically</p><p>&bull; Alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)</p><p>o Liver enzymes should be assessed every two weeks during the first 6 months of treatment, and every 8 weeks thereafter or as indicated by clinical signs and symptoms such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine. For ALT (SGPT) elevations between 2- and 3-fold the upper limit of normal, monitoring must be performed weekly.</p><p>&bull; Complete blood cell counts should be performed based on clinical signs and symptoms (e.g. infections) during treatment.</p><p><u>Accelerated elimination procedure</u></p><p>Teriflunomide is eliminated slowly from the plasma. Without an accelerated elimination procedure, it takes an average of 8 months to reach plasma concentrations less than 0.02 mg/l, although due to individual variation in substance clearance it may take up to 2 years. An accelerated elimination procedure can be used at any time after discontinuation of teriflunomide (see sections 4.6 and 5.2 for procedural details).</p><p><u>Hepatic effects</u></p><p>Elevations of liver enzymes have been observed in patients receiving teriflunomide (see section 4.8). These elevations occurred mostly within the first 6 months of treatment.</p><p>Teriflunomide therapy should be discontinued if liver injury is suspected; consider discontinuing teriflunomide therapy if elevated liver enzymes (greater than 3-fold ULN) are confirmed.</p><p>Patients with pre-existing liver disease and/or who consume substantial quantities of alcohol may be at increased risk of developing elevated liver enzymes when taking teriflunomide and should be closely monitored for signals of liver disease.</p><p><u>Hypoproteinaemia</u></p><p>Since teriflunomide is highly protein bound and as the binding is dependent upon the concentrations of albumin, unbound plasma teriflunomide concentrations are expected to be increased in patients with hypoproteinaemia, e.g. in nephrotic syndrome. Teriflunomide should not be used in patients with conditions of severe hypoproteinaemia.</p><p><u>Blood pressure</u></p><p>Elevation of blood pressure may occur during treatment with teriflunomide (see section 4.8). Blood pressure must be checked before the start of teriflunomide treatment and periodically thereafter. Blood pressure elevation should be appropriately managed before and during treatment with teriflunomide.</p><p><u>Infections</u></p><p>Initiation of treatment with teriflunomide should be delayed in patients with severe active infection until resolution.</p><p>In placebo-controlled studies, no increase in serious infections was observed with teriflunomide (see section 4.8). However, based on the immunomodulatory effect of teriflunomide, if a patient develops a serious infection, suspending treatment with <strong>Axyla </strong>should be considered and the benefits and risks should be reassessed prior to re-initiation of therapy. Due to the prolonged half-life, accelerated elimination with cholestyramine or charcoal may be considered.</p><p>Patients receiving <strong>Axyla </strong>should be instructed to report symptoms of infections to a physician. Patients with active acute or chronic infections should not start treatment with <strong>Axyla </strong>until the infection(s) is resolved.</p><p>The safety of teriflunomide in individuals with latent tuberculosis infection is unknown, as tuberculosis screening was not systematically performed in clinical studies. For patients testing positive in tuberculosis screening, treat by standard medical practice prior to therapy with <strong>Axyla</strong>.</p><p><u>Respiratory reactions</u></p><p>Interstitial lung disease (ILD) has been reported with teriflunomide in the postmarketing setting.</p><p>ILD and worsening of pre-existing ILD have been reported during treatment with leflunomide, the parent compound of teriflunomide. The risk is increased in patients who had a history of ILD when treated with leflunomide.</p><p>ILD may occur acutely at any time during therapy with a variable clinical presentation.</p><p>ILD may be fatal. New onset or worsening pulmonary symptoms, such as persistent cough and dyspnoea, may be a reason for discontinuation of the therapy and for further investigation, as appropriate. If discontinuation of the medicinal product is necessary, initiation of an accelerated elimination procedure should be considered.</p><p><u>Haematological effects</u></p><p>A mean decrease less than 15% from baseline affecting white blood cell count has been observed (see section 4.8). As a precaution, a recent complete blood cell count, including differential white blood cell count and platelets, should be available before the initiation of treatment with <strong>Axyla </strong>and the complete blood cell count should be assessed during <strong>Axyla </strong>therapy as indicated by clinical signs and symptoms (e.g., infections).</p><p>In patients with pre-existing anaemia, leucopenia, and /or thrombocytopenia as well as in patients with impaired bone marrow function or those at risk of bone marrow suppression, the risk of haematological disorders is increased. If such effects occur, the accelerated elimination<strong>&nbsp;</strong>procedure (see above) to reduce plasma levels of teriflunomide should be considered.</p><p>In cases of severe haematological reactions, including pancytopenia, <strong>Axyla </strong>and any concomitant myelosuppressive treatment must be discontinued and a teriflunomide accelerated elimination procedure should be considered.</p><p><u>Skin reactions</u></p><p>Cases of severe skin reactions have been reported postmarketing (including Stevens-Johnson syndrome and toxic epidermal necrolysis).</p><p>In patients treated with leflunomide, the parent compound, very rare cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported.</p><p>In case of ulcerative stomatitis, teriflunomide administration should be discontinued. If skin and /or mucosal reactions are observed which raise the suspicion of severe generalised major skin reactions (Stevens-Johnson syndrome, or toxic epidermal necrolysis-Lyell&#39;s syndrome), teriflunomide and any other possibly associated treatment must be discontinued, and an accelerated procedure initiated immediately. In such cases patients should not be re-exposed to teriflunomide (see section 4.3).</p><p>New onset of psoriasis (including pustular psoriasis) and worsening of pre-existing psoriasis have been reported during the use of teriflunomide. Treatment withdrawal and initiation of an accelerated elimination procedure may be considered taking into account patient&#39;s disease and medical history.</p><p><u>Peripheral neuropathy</u></p><p>Cases of peripheral neuropathy have been reported in patients receiving <strong>Axyla </strong>(see section 4.8). Most patients improved after discontinuation of <strong>Axyla</strong>. However, there was a wide variability in final outcome, i.e. in some patients the neuropathy resolved and some patients had persistent symptoms. If a patient taking <strong>Axyla </strong>develops a confirmed peripheral neuropathy, consider discontinuing <strong>Axyla </strong>therapy and performing the accelerated elimination procedure.</p><p><u>Vaccination</u></p><p>Two clinical studies have shown that vaccinations to inactivated neoantigen (first vaccination), or recall antigen (reexposure) were safe and effective during <strong>Axyla </strong>treatment. The use of live attenuated vaccines may carry a risk of infections and should therefore be avoided.</p><p>&nbsp;</p><p><u>Immunosuppressive or immunomodulating therapies</u></p><p>As leflunomide is the parent compound of teriflunomide, co-administration of teriflunomide with leflunomide is not recommended.</p><p>Co-administration with antineoplastic or immunosuppressive therapies used for treatment of MS has not been evaluated. Safety studies, in which teriflunomide was concomitantly administered with interferon beta or with glatiramer acetate for up to one year did not reveal any specific safety concerns, but a higher adverse reaction rate as compared to teriflunomide monotherapy was observed. The long term safety of these combinations in the treatment of multiple sclerosis has not been established.</p><p><u>Switching to or from <strong>Axyla</strong></u></p><p>Based on the clinical data related to concomitant administration of teriflunomide with interferon beta or with glatiramer acetate, no waiting period is required when initiating teriflunomide after interferon beta or glatiramer acetate or when starting interferon beta or glatiramer acetate, after teriflunomide.</p><p>Due to the long half-life of natalizumab, concomitant exposure, and thus concomitant immune effects, could occur for up to 2-3 months following discontinuation of natalizumab if <strong>Axyla </strong>was immediately started. Therefore, caution is required when switching patients from natalizumab to <strong>Axyla</strong>.</p><p>Based on the half-life of fingolimod, a 6-week interval without therapy is needed for clearance from the circulation and a 1 to 2 month period is needed for lymphocytes to return to normal range following discontinuation of fingolimod. Starting <strong>Axyla </strong>during this interval will result in concomitant exposure to fingolimod. This may lead to an additive effect on the immune system and caution is, therefore, indicated.</p><p>In MS patients, the median t<sub>1/2z</sub>&nbsp;was approximately 19 days after repeated doses of 14 mg. If a decision is made to stop treatment with <strong>Axyla</strong>, during the interval of 5 half-lives (approximately 3.5 months although may be longer in some patients), starting other therapies will result in concomitant exposure to <strong>Axyla</strong>. This may lead to an additive effect on the immune system and caution is, therefore, indicated.</p><p><u>Lactose</u></p><p>Since <strong>Axyla </strong>tablets contain lactose, patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption, should not take this medicinal product.</p><p><u>Interference with determination of ionised calcium levels</u></p><p>The measurement of ionised calcium levels might show falsely decreased values under treatment with leflunomide and/or teriflunomide (the active metabolite of leflunomide) depending on the type of ionised calcium analyser used (e.g. blood gas analyser). Therefore, the plausibility of observed decreased ionised calcium levels needs to be questioned in patients under treatment with leflunomide or teriflunomide. In case of doubtful measurements, it is recommended to determine the total albumin adjusted serum calcium concentration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacokinetic interactions of other substances on teriflunomide</u></p><p>The primary biotransformation pathway for teriflunomide is hydrolysis, with oxidation being a minor pathway.</p><p><em>Potent cytochrome P450 (CYP) and transporter inducers</em></p><p>Co-administration of repeated doses (600 mg once daily for 22 days) of rifampicin (a CYP2B6, 2C8, 2C9, 2C19, 3A inducer), as well as an inducer of the efflux transporters P-glycoprotein [P-gp] and breast cancer resistant protein [BCRP] with teriflunomide (70 mg single dose) resulted in an approximately 40% decrease in teriflunomide exposure. Rifampicin and other known potent CYP and transporter inducers such as carbamazepine, phenobarbital, phenytoin and St John&#39;s Wort should be used with caution during the treatment with teriflunomide.</p><p><em>Cholestyramine or activated charcoal</em></p><p>It is recommended that patients receiving teriflunomide are not treated with cholestyramine or activated charcoal because this leads to a rapid and significant decrease in plasma concentration unless an accelerated elimination is desired. The mechanism is thought to be by interruption of enterohepatic recycling and/or gastrointestinal dialysis of teriflunomide.</p><p><u>Pharmacokinetic interactions of teriflunomide on other substances</u></p><p><em>Effect of teriflunomide on CYP2C8 substrate: repaglinide</em></p><p>There was an increase in mean repaglinide C<sub>max</sub>&nbsp;and AUC (1.7- and 2.4-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of CYP2C8&nbsp;<em>in vivo</em>. Therefore, medicinal products metabolised by CYP2C8, such as repaglinide, paclitaxel, pioglitazone or rosiglitazone, should be used with caution during treatment with teriflunomide.</p><p><em>Effect of teriflunomide on oral contraceptives: 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel</em></p><p>There was an increase in mean ethinylestradiol C<sub>max</sub>&nbsp;and AUC<sub>0-24&nbsp;</sub>(1.58- and 1.54-fold, respectively) and levonorgestrel C<sub>max</sub>&nbsp;and AUC<sub>0-24&nbsp;</sub>(1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide. While this interaction of teriflunomide is not expected to adversely impact the efficacy of oral contraceptives, it should be considered when selecting or adjusting oral contraceptive treatment used in combination with teriflunomide.</p><p><em>Effect of teriflunomide on CYP1A2 substrate: caffeine</em></p><p>Repeated doses of teriflunomide decreased mean C<sub>max&nbsp;</sub>and AUC of caffeine (CYP1A2 substrate) by 18% and 55%, respectively, suggesting that teriflunomide may be a weak inducer of CYP1A2&nbsp;<em>in vivo</em>. Therefore, medicinal products metabolised by CYP1A2 (such as duloxetin, alosetron, theophylline and tizanidine) should be used with caution during treatment with teriflunomide, as it could lead to the reduction of the efficacy of these medicinal products.</p><p><em>Effect of teriflunomide on warfarin</em></p><p>Repeated doses of teriflunomide had no effect on the pharmacokinetics of S-warfarin, indicating that teriflunomide is not an inhibitor or an inducer of CYP2C9. However, a 25% decrease in peak international normalised ratio (INR) was observed when teriflunomide was coadministered with warfarin as compared with warfarin alone. Therefore, when warfarin is co-administered with teriflunomide, close INR follow-up and monitoring is recommended.</p><p><em>Effect of teriflunomide on organic anion transporter 3 (OAT3) substrates</em></p><p>There was an increase in mean cefaclor C<sub>max</sub>&nbsp;and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of OAT3&nbsp;<em>in vivo</em>. Therefore, when teriflunomide is coadministered with substrates of OAT3, such as cefaclor, benzylpenicillin, ciprofloxacin, indometacin, ketoprofen, furosemide, cimetidine, methotrexate, zidovudine, caution is recommended.</p><p><em>Effect of teriflunomide on BCRP and /or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3) substrates</em></p><p>There was an increase in mean rosuvastatin C<sub>max</sub>&nbsp;and AUC (2.65- and 2.51-fold, respectively), following repeated doses of teriflunomide. However, there was no apparent impact of this increase in plasma rosuvastatin exposure on the HMG-CoA reductase activity. For rosuvastatin, a dose reduction by 50% is recommended for coadministration with teriflunomide. For other substrates of BCRP (e.g., methotrexate, topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-Co reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide, repaglinide, rifampicin) concomitant administration of teriflunomide should also be undertaken with caution. Patients should be closely monitored for signs and symptoms of excessive exposure to the medicinal products and reduction of the dose of these medicinal products should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Use in males</u></p><p>The risk of male-mediated embryo-foetal toxicity through teriflunomide treatment is considered low (see section 5.3).</p><p><u>Pregnancy</u></p><p>There are limited amount of data from the use of teriflunomide in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Teriflunomide may cause serious birth defects when administered during pregnancy. Teriflunomide is contraindicated in pregnancy (see section 4.3).</p><p>Women of childbearing potential have to use effective contraception during treatment and after treatment as long as teriflunomide plasma concentration is above 0.02 mg/l. During this period women should discuss any plans to stop or change contraception with the treating physician.</p><p>The patient must be advised that if there is any delay in onset of menses or any other reason to suspect pregnancy, they must notify the physician immediately for pregnancy testing, and if positive, the physician and patient must discuss the risk to the pregnancy. It is possible that rapidly lowering the blood level of teriflunomide, by instituting the accelerated elimination procedure described below, at the first delay of menses, may decrease the risk to the foetus.</p><p>For women receiving teriflunomide treatment, who wish to become pregnant, the medicinal product should be stopped and an accelerated elimination procedure is recommended in order to more rapidly achieve concentration below 0.02 mg/l (see below).</p><p>If an accelerated elimination procedure is not used, teriflunomide plasma levels can be expected to be above 0.02 mg/l for an average of 8 months, however, in some patients it may take up to 2 years to reach plasma concentration below 0.02 mg/l. Therefore, teriflunomide plasma concentrations should be measured before a woman begins to attempt to become pregnant. Once the teriflunomide plasma concentration is determined to be below 0.02 mg/l, the plasma concentration must be determined again after an interval of at least 14 days. If both plasma concentrations are below 0.02 mg/l, no risk to the foetus is to be expected.</p><p>For further information on the sample testing please contact the Marketing Authorisation Holder or its local representative (see section 7).</p><p><em>Accelerated elimination procedure</em></p><p>After stopping treatment with teriflunomide:</p><p>&bull; cholestyramine 8 g is administered 3 times daily for a period of 11 days, or cholestyramine 4 g three times a day can be used, if cholestyramine 8 g three times a day is not well tolerated,</p><p>&bull; alternatively, 50 g of activated powdered charcoal is administered every 12 hours for a period of 11 days.</p><p>However, also following either of the accelerated elimination procedures, verification by 2 separate tests at an interval of at least 14 days and a waiting period of one-and-a-half months between the first occurrence of a plasma concentration below 0.02 mg/l and fertilisation is required.</p><p>Both cholestyramine and activated powdered charcoal may influence the absorption of oestrogens and progestogens such that reliable contraception with oral contraceptives may not be guaranteed during the accelerated elimination procedure with cholestyramine or activated powdered charcoal. Use of alternative contraceptive methods is recommended.</p><p><u>Breast-feeding</u></p><p>Animal studies have shown excretion of teriflunomide in milk. Teriflunomide is contraindicated during breast-feeding (see section 4.3).</p><p><u>Fertility</u></p><p>Results of studies in animals have not shown an effect on fertility (see section 5.3). Although human data are lacking, no effect on male and female fertility is anticipated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Axyla </strong>has no or negligible influence on the ability to drive and use machines.</p><p>In the case of adverse reactions such as dizziness, which has been reported with leflunomide, the parent compound, the patient&#39;s ability to concentrate and to react properly may be impaired. In such cases, patients should refrain from driving and using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>A total of 2267 patients were exposed to teriflunomide (1155 on teriflunomide 7 mg and 1112 on teriflunomide 14 mg) once daily for a median duration of about 672 days in four placebo-controlled studies (1045 and 1002 patients for teriflunomide 7 mg and 14 mg, respectively) and one active comparator study (110 patients in each of the teriflunomide treatment groups) in patients with relapsing forms of MS (Relapsing Multiple Sclerosis, RMS).</p><p>Teriflunomide is the main metabolite of leflunomide. The safety profile of leflunomide in patients suffering from rheumatoid arthritis or psoriatic arthritis may be pertinent when prescribing teriflunomide in MS patients.</p><p>The placebo-controlled pooled analysis was based on 2047 patients with Relapsing Multiple Sclerosis treated with teriflunomide once daily. Within this safety population, the most commonly reported adverse reactions in the teriflunomide treated patients were: headache, diarrhoea, increased ALT, nausea, and alopecia. In general, headache, diarrhoea, nausea and alopecia, were mild to moderate, transient and infrequently led to treatment discontinuation.</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions reported with <strong>Axyla </strong>in placebo-controlled studies, reported for teriflunomide 7 mg or 14 mg at &ge; 1% higher rate than for placebo, are shown below. Frequencies were defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Influenza, Upper respiratory tract infection, Urinary tract infection, Bronchitis, Sinusitis, Pharyngitis, Cystitis, Gastroenteritis viral, Oral herpes, Tooth infection, Laryngitis, Tinea pedis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Severe infections including sepsis<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Neutropenia<sup>b</sup>, Anaemia</p></td><td style="vertical-align:top"><p>Mild thrombocytopenia (platelets &lt;100G/l)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Mild allergic reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyper-sensitivity reactions (immediate or delayed) including anaphylaxis and angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Paraesthesia, Sciatica, Carpal tunnel syndrome</p></td><td style="vertical-align:top"><p>Hyperaesthesia, Neuralgia, Peripheral neuropathy</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypertension<sup>b</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Interstitial lung disease</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea, Nausea</p></td><td style="vertical-align:top"><p>Abdominal pain upper, Vomiting, Toothache</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pancreatitis, Stomatitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Alanine aminotransferase (ALT) increase<sup>b</sup></p></td><td style="vertical-align:top"><p>Gamma-glutamyltransferase (GGT) increase<sup>b</sup>, Aspartate aminotransferase increase<sup>b</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Acute hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dyslipidaemia</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Rash, Acne</p></td><td style="vertical-align:top"><p>Nail disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Severe skin reactions<sup>a</sup>, Psoriasis (including pustular)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Musculoskeletal pain, Myalgia, Arthralgia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pollakiuria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Menorrhagia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pain, Asthenia<sup>a</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Weight decrease, Neutrophil count decrease<sup>b</sup>, White blood cell count decrease<sup>b</sup>, Blood creatine phosphokinase increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Post-traumatic pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>a: please refer to the detailed description section</p><p>b: see section 4.4</p><p><u>Description of selected adverse reactions</u></p><p><em>Alopecia</em></p><p>Alopecia was reported as hair thinning, decreased hair density, hair loss, associated or not with hair texture change, in 13.9% of patients treated with 14 mg teriflunomide versus 5.1% in patients treated with placebo. Most cases were described as diffuse or generalised over the scalp (no complete hair loss reported) and occurred most often during the first 6 months and with resolution in 121 of 139 (87.1%) patients treated with teriflunomide 14 mg. Discontinuation because of alopecia was 1.3% in the teriflunomide 14 mg teriflunomide group, versus 0.1% in the placebo group.</p><p><em>Hepatic effects</em></p><p>During placebo-controlled studies the following was detected:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="3" style="vertical-align:bottom"><p><strong>ALT increase (based on laboratory data) according to baseline status - Safety population in placebo-controlled studies</strong></p></td></tr><tr><td style="vertical-align:bottom">&nbsp;</td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>(N=997)</strong></p></td><td style="vertical-align:bottom"><p><strong>Teriflunomide 14 mg</strong></p><p><strong>(N=1002)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&gt;3 ULN</p></td><td style="vertical-align:bottom"><p>66/994 (6.6%)</p></td><td style="vertical-align:bottom"><p>80/999 (8.0%)</p></td></tr><tr><td style="vertical-align:bottom"><p>&gt;5 ULN</p></td><td style="vertical-align:bottom"><p>37/994 (3.7%)</p></td><td style="vertical-align:bottom"><p>31/999 (3.1%)</p></td></tr><tr><td style="vertical-align:bottom"><p>&gt;10 ULN</p></td><td style="vertical-align:bottom"><p>16/994 (1.6%)</p></td><td style="vertical-align:bottom"><p>9/999 (0.9%)</p></td></tr><tr><td style="vertical-align:bottom"><p>&gt;20 ULN</p></td><td style="vertical-align:bottom"><p>4/994 (0.4%)</p></td><td style="vertical-align:bottom"><p>3/999 (0.3%)</p></td></tr><tr><td style="vertical-align:bottom"><p>ALT &gt;3 ULN and TBILI &gt;2 ULN</p></td><td style="vertical-align:bottom"><p>5/994 (0.5%)</p></td><td style="vertical-align:bottom"><p>3/999 (0.3%)</p></td></tr></tbody></table><p>Mild increases in transaminase, ALT below or equal to 3-fold ULN were more frequently seen in teriflunomide-treated groups as compared to placebo. The frequency of elevations above 3-fold ULN and higher was balanced across treatment groups. These elevations in transaminase occurred mostly within the first 6 months of treatment and were reversible after treatment cessation. The recovery time varied between months and years.</p><p><em>Blood pressure effects</em></p><p>In placebo-controlled studies the following was established:</p><p>- systolic blood pressure was &gt;140 mm Hg in 19.9% of patients receiving 14 mg/day teriflunomide as compared to 15.5% receiving placebo;</p><p>- systolic blood pressure was &gt;160 mm Hg in 3.8% of patients receiving 14 mg/day teriflunomide as compared to 2.0% receiving placebo;</p><p>- diastolic blood pressure was &gt;90 mm Hg in 21.4% of patients receiving 14 mg/day teriflunomide as compared to 13.6% receiving placebo.</p><p><em>Infections</em></p><p>In placebo-controlled studies, no increase in serious infections was observed with teriflunomide 14 mg (2.7%) as compared to placebo (2.2%). Serious opportunistic infections occurred in 0.2% of each group. Severe infections including sepsis, sometimes fatal have been reported postmarketing.</p><p><em>Haematological effects</em></p><p>A mean decrease affecting white blood cell (WBC) count (&lt;15% from baseline levels, mainly neutrophil and lymphocytes decrease) was observed in placebo-controlled trials with <strong>AXYLA</strong>, although a greater decrease was observed in some patients. The decrease in mean count from baseline occurred during the first 6 weeks then stabilised over time while on-treatment but at decreased levels (less than a 15% decrease from baseline). The effect on red blood cell (RBC) (&lt;2%) and platelet counts (&lt;10%) was less pronounced.</p><p><em>Peripheral neuropathy</em></p><p>In placebo-controlled studies, peripheral neuropathy, including both polyneuropathy and mononeuropathy (e.g., carpal tunnel syndrome), was reported more frequently in patients taking teriflunomide than in patients taking placebo. In the pivotal, placebo-controlled studies, the incidence of peripheral neuropathy confirmed by nerve conduction studies was 1.9% (17 patients out of 898) on 14 mg of teriflunomide, compared with 0.4% (4 patients out of 898) on placebo. Treatment was discontinued in 5 patients with peripheral neuropathy on teriflunomide 14 mg. Recovery following treatment discontinuation was reported in 4 of these patients.</p><p><em>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</em></p><p>There does not appear to be an increased risk of malignancy with teriflunomide in the clinical trial experience. The risk of malignancy, particularly lymphoproliferative disorders, is increased with use of some other agents that affect the immune system (class effect).</p><p><em>Severe skin reactions</em></p><p>Cases of severe skin reactions have been reported with teriflunomide post-marketing (see section 4.4).</p><p><em>Asthenia</em></p><p>In placebo-controlled studies, frequencies for asthenia were 2.0%, 1.6% and 2.2% in the placebo, teriflunomide 7 mg and teriflunomide 14 mg group, respectively.</p><p><u>&nbsp;</u></p><p><strong>To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:.65pt;margin-top:6.2pt;width:375.05pt;height:84.2pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=right style='text-align:right;mso-layout-grid-align:
    none;text-autospace:none'><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>National Pharmacovigilance and Drug
    Safety Centre (NPC) :<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>SFDA Call
    Center: 19999<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    class=MsoHyperlink><span style='font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol;text-decoration:none;text-underline:
    none'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span></span><![endif]><span dir=LTR></span><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>E-mail:
    </span><a href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>npc.drug@sfda.gov.sa</span></a><span
    class=MsoHyperlink><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></span></p>
    <p class=MsoListParagraphCxSpLast style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "Times New Roman",serif'>Website: <span style='color:black;mso-themecolor:
    text1'>https://ade.sfda.gov.sa</span> </span><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="506" height="119" alt="Text Box: National Pharmacovigilance and Drug Safety Centre (NPC) :
•	SFDA Call Center: 19999
•	E-mail: npc.drug@sfda.gov.sa
•	Website: https://ade.sfda.gov.sa 
" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>There is no experience regarding teriflunomide overdose or intoxication in humans. Teriflunomide 70 mg daily was administered up to 14 days in healthy subjects. The adverse reactions were consistent with the safety profile for teriflunomide in MS patients.</p><p><u>Management</u></p><p>In the event of relevant overdose or toxicity, cholestyramine or activated charcoal is recommended to accelerate elimination. The recommended elimination procedure is cholestyramine 8 g three times a day for 11 days. If this is not well tolerated, cholestyramine 4 g three times a day for 11 days can be used. Alternatively, when cholestyramine is not available, activated charcoal 50 g twice a day for 11 days may also be used. In addition, if required for tolerability reasons, administration of cholestyramine or activated charcoal does not need to occur on consecutive days (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 Pharmacodynamic properties</strong></p><p>Pharmacotherapeutic group: Immunosuppressants, Selective immunosuppressants, ATC Code: L04AA31</p><p><u>Mechanism of action</u></p><p>Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHO-DH), required for the de novo pyrimidine synthesis. As a consequence teriflunomide reduces the proliferation of dividing cells that need de novo synthesis of pyrimidine to expand. The exact mechanism by which teriflunomide exerts its therapeutic effect in MS is not fully understood, but this is mediated by a reduced number of lymphocytes.</p><p><u>Pharmacodynamic effects</u></p><p><em>Immune system</em></p><p>Effects on immune cell numbers in the blood: In the placebo-controlled studies, teriflunomide 14 mg once a day led to a mild mean reduction in lymphocyte count, of less than 0.3 x 10<sup>9</sup>/l, which occurred over the first 3 months of treatment and levels were maintained until the end of the treatment.</p><p><em>Potential to prolong the QT interval</em></p><p>In a placebo-controlled thorough QT study performed in healthy subjects, teriflunomide at mean steady-state concentrations did not show any potential for prolonging the QTcF interval compared with placebo: the largest time matched mean difference between teriflunomide and placebo was 3.45 ms with the upper bound of the 90% CI being 6.45 ms.</p><p><em>Effect on renal tubular functions</em></p><p>In the placebo-controlled studies, mean decreases in serum uric acid at a range of 20 to 30% were observed in patients treated with teriflunomide compared to placebo. Mean decrease in serum phosphorus was around 10% in the teriflunomide group compared to placebo. These effects are considered to be related to increase in renal tubular excretion and not related to changes in glomerular functions.</p><p><u>Clinical efficacy and safety</u></p><p>The efficacy of <strong>Axyla </strong>was demonstrated in two placebo controlled studies, the TEMSO and the TOWER study, that evaluated once daily doses of teriflunomide 7 mg and 14 mg in patients with RMS.</p><p>A total of 1088 patients with RMS were randomised in TEMSO to receive 7 mg (n=366) or 14 mg (n=359) of teriflunomide or placebo (n= 363) for 108 weeks duration. All patients had a definite diagnosis of MS (based on McDonald criteria (2001)), exhibited a relapsing clinical course, with or without progression, and experienced at least 1 relapse over the year preceding the trial or at least 2 relapses over the 2 years preceding the trial. At entry, patients had an Expanded Disability Status Scale (EDSS) score &le;5.5.</p><p>The mean age of the study population was 37.9 years. The majority of patients had relapsing&ndash;remitting multiple sclerosis (91.5%), but a subgroup of patients had secondary progressive (4.7%) or progressive relapsing multiple sclerosis (3.9%). The mean number of relapses within the year before study inclusion was 1.4 with 36.2% of patients having gadolinium-enhancing lesions at baseline. The median EDSS score at baseline was 2.50<strong>;&nbsp;</strong>249 patients (22.9%) had an EDSS score &rsaquo; 3.5 at baseline. The mean duration of disease, since first symptoms, was 8.7 years. A majority of patients (73%) had not received disease-modifying therapy during the 2 years before study entry. The study results are shown in Table 1.</p><p>Long term follow-up results from TEMSO long term extension safety study (overall median treatment duration approximately 5 years, maximum treatment duration approximately 8.5 years) did not present any new or unexpected safety findings.</p><p>A total of 1169 patients with RMS were randomised in TOWER to receive 7 mg (n=408) or 14 mg (n=372) of teriflunomide or placebo (n= 389) for a variable treatment duration ending at 48 weeks after last patient randomised. All patients had a definite diagnosis of MS (based on McDonald criteria (2005)), exhibited a relapsing clinical course, with or without progression, and experienced at least 1 relapse over the year preceding the trial or at least 2 relapses over the 2 years preceding the trial. At entry, patients had an Expanded Disability Status Scale (EDSS) score &le;5.5.</p><p>The mean age of the study population was 37.9 years. The majority of patients had relapsing&ndash;remitting multiple sclerosis (97.5%), but a subgroup of patients had secondary progressive (0.8%) or progressive relapsing multiple sclerosis (1.7%). The mean number of relapses within the year before study inclusion was 1.4. Gadolinium-enhancing lesions at baseline: no data. The median EDSS score at baseline was 2.50; 298 patients (25.5%) had an EDSS score &rsaquo; 3.5 at baseline. The mean duration of disease, since first symptoms, was 8.0 years. A majority of patients (67.2%) had not received disease-modifying therapy during the 2 years before study entry. The study results are shown in Table 1.</p><p><strong>Table 1 - Main Results ( for the approved dose, ITT population)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td>&nbsp;</td><td colspan="2"><p><strong>TEMSO-study</strong></p></td><td colspan="2"><p><strong>TOWER-study</strong></p></td></tr><tr><td>&nbsp;</td><td><p><strong>Teriflunomide</strong></p><p><strong>14 mg</strong></p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>Teriflunomide</strong></p><p><strong>14 mg</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>N</p></td><td><p><strong>358</strong></p></td><td><p><strong>363</strong></p></td><td><p><strong>370</strong></p></td><td><p><strong>388</strong></p></td></tr><tr><td><p><strong>Clinical Outcomes</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Annualised relapse rate</p></td><td><p>0.37</p></td><td><p>0.54</p></td><td><p>0.32</p></td><td><p>0.50</p></td></tr><tr><td><p><em>Risk difference (CI<sub>95%</sub>)</em></p></td><td colspan="2"><p>-0.17 (-0.26, -0.08)***</p></td><td colspan="2"><p>-0.18 (-0.27, -0.09)****</p></td></tr><tr><td><p>Relapse-free&nbsp;<sub>week 108</sub></p></td><td><p>56.5%</p></td><td><p>45.6%</p></td><td><p>57.1%</p></td><td><p>46.8%</p></td></tr><tr><td><p>Hazard ratio (CI95%)</p></td><td colspan="2"><p>0.72, (0.58, 0.89)**</p></td><td colspan="2"><p>0.63, (0.50, 0.79)****</p></td></tr><tr><td><p>3-month Sustained Disability Progression&nbsp;<sub>week 108</sub></p></td><td><p>20.2%</p></td><td><p>27.3%</p></td><td><p>15.8%</p></td><td><p>19.7%</p></td></tr><tr><td><p><em>Hazard ratio (CI<sub>95%</sub>)</em></p></td><td colspan="2"><p>0.70 (0.51, 0.97)*</p></td><td colspan="2"><p>0.68 (0.47, 1.00)*</p></td></tr><tr><td><p>6-month Sustained Disability Progression&nbsp;<sub>week 108</sub></p></td><td><p>13.8%</p></td><td><p>18.7%</p></td><td><p>11.7%</p></td><td><p>11.9%</p></td></tr><tr><td><p><em>Hazard ratio (CI<sub>95%</sub>)</em></p></td><td colspan="2"><p>0.75 (0.50, 1.11)</p></td><td colspan="2"><p>0.84 (0.53, 1.33)</p></td></tr><tr><td><p><strong>MRI endpoints</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2" rowspan="7"><p>Not measured</p></td></tr><tr><td><p>Change in BOD&nbsp;<sub>week 108</sub><sup>(1)</sup></p></td><td><p>0.72</p></td><td><p>2.21</p></td></tr><tr><td><p><em>Change relative to placebo</em></p></td><td colspan="2"><p>67%***</p></td></tr><tr><td><p>Mean Number of Gd-enhancing lesions at week 108</p></td><td><p>0.38</p></td><td><p>1.18</p></td></tr><tr><td><p><em>Change relative to placebo (CI<sub>95%</sub>)</em></p></td><td colspan="2"><p>-0.80 (-1.20, -0.39)****</p></td></tr><tr><td><p>Number of unique active lesions /scan</p></td><td><p>0.75</p></td><td><p>2.46</p></td></tr><tr><td><p><em>Change relative to placebo (CI<sub>95%</sub>)</em></p></td><td colspan="2"><p>69%, (59%; 77%)****</p></td></tr></tbody></table><p>**** p&lt;0.0001 *** p&lt;0.001 ** p&lt;0.01 * p&lt;0.05 compared to placebo</p><p>(1) BOD: burden of disease: total lesion volume (T2 and T1 hypointense) in ml</p><p>Efficacy in patients with high disease activity:</p><p>A consistent treatment effect on relapses and time to 3-month sustained disability progression in a subgroup of patients in TEMSO (n= 127) with high disease activity was observed. Due to the design of the study, high disease activity was defined as 2 or more relapses in one year, and with one or more Gd-enhancing lesion on brain MRI. No similar subgroup analysis was performed in TOWER as no MRI data were obtained.</p><p>No data are available in patients who have failed to respond to a full and adequate course (normally at least one year of treatment) of beta-interferon, having had at least 1 relapse in the previous year while on therapy, and at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gd-enhancing lesion, or patients having an unchanged or increased relapse rate in the prior year as compared to the previous 2 years.</p><p>TOPIC was a double-blind, placebo-controlled study that evaluated once daily doses of teriflunomide 7 mg and 14 mg for up to 108 weeks in patients with first clinical demyelinating event (mean age 32.1 years). The primary endpoint was time to a second clinical episode (relapse). A total of 618 patients were randomised to receive 7 mg (n=205) or 14 mg (n=216) of teriflunomide or placebo (n=197). The risk of a second clinical attack over 2 years was 35.9% in the placebo group and 24.0% in the teriflunomide 14 mg treatment group (hazard ratio: 0.57, 95% confidence interval: 0.38 to 0.87, p=0.0087). The results from the TOPIC study confirmed the efficacy of teriflunomide in RRMS (including early RRMS with first clinical demyelinating event and MRI lesions disseminated in time and space).</p><p>Teriflunomide effectiveness was compared to that of a subcutaneous interferon beta-1a (at the recommended dose of 44 &micro;g three times a week) in 324 randomised patients in a study (TENERE) with minimum treatment duration of 48 weeks (maximum 114 weeks). The risk of failure (confirmed relapse or permanent treatment discontinuation whichever came first) was the primary endpoint. The number of patients with permanent treatment discontinuation in the teriflunomide 14 mg group was 22 out of 111 (19.8%), the reasons being adverse events (10.8%), lack of efficacy (3.6%), other reason (4.5%) and lost to follow-up (0.9%). The number of patients with permanent treatment discontinuation in the subcutaneous interferon beta-1a group was 30 out of 104 (28 .8%), the reasons being adverse events (21.2%), lack of efficacy (1.9%), other reason (4.8%) and poor compliance to protocol (1%). Teriflunomide 14 mg/day was not superior to interferon beta-1a on the primary endpoint: the estimated percentage of patients with treatment failure at 96 weeks using the Kaplan-Meier method was 41.1% versus 44.4% (teriflunomide 14 mg versus interferon beta-1a group, p=0.595).</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with <strong>Axyla </strong>in children from birth to less than 10 years in treatment of multiple sclerosis (see section 4.2 for information on paediatric use).</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with <strong>Axyla </strong>in one or more subsets of the paediatric population in multiple sclerosis (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Median time to reach maximum plasma concentrations occurs between 1 to 4 hours post-dose following repeated oral administration of teriflunomide, with high bioavailability (approximately 100%).</p><p>Food does not have a clinically relevant effect on teriflunomide pharmacokinetics.</p><p>From the mean predicted pharmacokinetic parameters calculated from the population pharmacokinetic (PopPK) analysis using data from healthy volunteers and MS patients, there is a slow approach to steady-state concentration (i.e., approximately 100 days (3.5 months) to attain 95% of steady-state concentrations) and the estimated AUC accumulation ratio is approximately 34-fold.</p><p><u>Distribution</u></p><p>Teriflunomide is extensively bound to plasma protein (&gt;99%), probably albumin and is mainly distributed in plasma. The volume of distribution is 11 l after a single intravenous (IV) administration. However, this is most likely an underestimation since extensive organ distribution was observed in rats.</p><p><u>Biotransformation</u></p><p>Teriflunomide is moderately metabolised and is the only component detected in plasma. The primary biotransformation pathway for teriflunomide is hydrolysis with oxidation being a minor pathway. Secondary pathways involve oxidation, N-acetylation and sulfate conjugation.</p><p><u>Elimination</u></p><p>Teriflunomide is excreted in the gastrointestinal tract mainly through the bile as unchanged medicinal product and most likely by direct secretion. Teriflunomide is a substrate of the efflux transporter BCRP, which could be involved in direct secretion. Over 21 days, 60.1% of the administered dose is excreted via feces (37.5%) and urine (22.6%). After the rapid elimination procedure with cholestyramine, an additional 23.1% was recovered (mostly in feces). Based on individual prediction of pharmacokinetic parameters using the PopPK model of teriflunomide in healthy volunteers and MS patients, median t<sub>1/2z</sub>&nbsp;was approximately 19 days after repeated doses of 14 mg. After a single intravenous administration, the total body clearance of teriflunomide is 30.5 ml/h.</p><p><em>Accelerated Elimination Procedure: Cholestyramine and activated charcoal</em></p><p>The elimination of teriflunomide from the circulation can be accelerated by administration of cholestyramine or activated charcoal, presumably by interrupting the reabsorption processes at the intestinal level. Teriflunomide concentrations measured during an 11-day procedure to accelerate teriflunomide elimination with either 8 g cholestyramine three times a day, 4 g cholestyramine three times a day or 50 g activated charcoal twice a day following cessation of teriflunomide treatment have shown that these regimens were effective in accelerating teriflunomide elimination, leading to more than 98% decrease in teriflunomide plasma concentrations, with cholestyramine being faster than charcoal. Following discontinuation of teriflunomide and the administration of cholestyramine 8 g three times a day, the plasma concentration of teriflunomide is reduced 52% at the end of day 1, 91% at the end of day 3, 99.2% at the end of day 7, and 99.9% at the completion of day 11. The choice between the 3 elimination procedures should depend on the patient&#39;s tolerability. If cholestyramine 8 g three times a day is not well-tolerated, cholestyramine 4 g three times a day can be used. Alternatively, activated charcoal may also be used (the 11 days do not need to be consecutive unless there is a need to lower teriflunomide plasma concentration rapidly).</p><p><u>Linearity/non-linearity</u></p><p>Systemic exposure increases in a dose proportional manner after oral administration teriflunomide from 7 to 14 mg.</p><p><u>Characteristics in specific groups of patients</u></p><p><em>Gender, Elderly, Paediatric patients</em></p><p>Several sources of intrinsic variability were identified in healthy subjects and MS patients based on the PopPK analysis: age, body weight, gender, race, and albumin and bilirubin levels. Nevertheless, their impact remains limited (&le;31%).</p><p><em>Hepatic impairment</em></p><p>Mild and moderate hepatic impairment had no impact on the pharmacokinetic of teriflunomide. Therefore no dose adjustment is anticipated in mild and moderate hepatic-impaired patients. However, teriflunomide is contraindicated in patients with severe hepatic impairment (see sections 4.2 and 4.3).</p><p><em>Renal impairment</em></p><p>Severe renal impairment had no impact on the pharmacokinetic of teriflunomide. Therefore no dose adjustment is anticipated in mild, moderate and severe renal-impaired patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated oral administration of teriflunomide to mice, rats and dogs for up to 3, 6, and 12 months, respectively, revealed that the major targets of toxicity were the bone marrow, lymphoid organs, oral cavity/ gastro intestinal tract, reproductive organs, and pancreas. Evidence of an oxidative effect on red blood cells was also observed. Anemia, decreased platelet counts and effects on the immune system, including leukopenia, lymphopenia and secondary infections, were related to the effects on the bone marrow and/or lymphoid organs. The majority of effects reflect the basic mode of action of the compound (inhibition of dividing cells). Animals are more sensitive to the pharmacology, and therefore toxicity, of teriflunomide than humans. As a result, toxicity in animals was found at exposures equivalent or below human therapeutic levels.</p><p>Teriflunomide was not mutagenic&nbsp;<em>in vitro</em>&nbsp;or clastogenic&nbsp;<em>in vivo</em>. Clastogenicity observed&nbsp;<em>in vitro</em>&nbsp;was considered to be an indirect effect related to nucleotide pool imbalance resulting from the pharmacology of DHO-DH inhibition. The minor metabolite TFMA (4-trifluoromethylaniline) caused mutagenicity and clastogenicity&nbsp;<em>in vitro</em>&nbsp;but not&nbsp;<em>in vivo</em>.</p><p>No evidence of carcinogenicity was observed in rats and mice.</p><p>Fertility was unaffected in rats despite adverse effects of teriflunomide on male reproductive organs, including reduced sperm count. There were no external malformations in the offspring of male rats administered teriflunomide prior to mating with untreated female rats. Teriflunomide was embryotoxic and teratogenic in rats and rabbits at doses in the human therapeutic range. Adverse effects on the offspring were also seen when teriflunomide was administered to pregnant rats during gestation and lactation. The risk of male-mediated embryo-fetal toxicity through teriflunomide treatment is considered low. The estimated female plasma exposure via the semen of a treated patient is expected to be 100 times lower than the plasma exposure after 14 mg of oral teriflunomide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1 List of excipients</strong></p><p><u>Tablet core</u></p><p>lactose monohydrate</p><p>microcrystalline cellulose</p><p>sodium starch glycolate (Type A)</p><p>hydroxypropylcellulose</p><p>magnesium stearate</p><p>Colloidal Silicon Dioxide</p><p>Opadry Blue 03B505062</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.5 Nature and contents of container</strong></p><p>Alu-Alu blister pack containing tablets placed in a printed carton along with pack insert. Pack size: 28&rsquo;s (14&rsquo;s blister x 2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dec,2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>